HS 10353
Alternative Names: HS-10353Latest Information Update: 28 Feb 2024
At a glance
- Originator Jiangsu Hansoh Pharmaceutical
- Class Antidepressants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Major depressive disorder
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Major depressive disorder in China (PO, Capsule)
- 11 Jul 2023 Jiangsu Hansoh Pharmaceutical plans a phase II trial for Major depressive disorder (PO, Capsule), in August 2023 (NCT05938179)
- 10 Jul 2023 Jiangsu Hansoh Pharmaceutical plans a phase II trial for postpartum depression (PO, Capsule) in August 2023 (NCT05937867)